Trial Profile
Open-Label, Sequential, Ascending, Multi-Dose, Phase 1 Study of KW-2450 as Monotherapy in Subjects With Previously Treated Advanced Solid Tumor.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs KW 2450 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kyowa Kirin
- 01 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Dec 2009 New source identified and integrated (Barbara Ann Karmanos Cancer Institute, 2009-051).
- 11 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.